Does the lipid-lowering peroxisome proliferator-activated receptors ligand bezafibrate prevent colon cancer in patients with coronary artery disease?

Cardiovascular Diabetology

Volumn 7, Issue , 2008, Pages

  Tenenbaum, Alexander ^a,b   Boyko, Valentina ^a,b   Fisman, Enrique Z ^a,b   Goldenberg, Ilan ^a,b   Adler, Yehuda ^a,b   Feinberg, Micha S ^a,b   Motro, Michael ^a,b   Tanne, David ^a,b   Shemesh, Joseph ^a,b   Schwammenthal, Ehud ^a,b   Behar, Solomon ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; BEZAFIBRATE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PLACEBO; LIGAND; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PREVENTION; CANCER REGISTRY; CANCER RISK; CLINICAL TRIAL; COLON CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; AGED; COLON TUMOR; DOSE RESPONSE; DRUG ANTAGONISM; INCIDENCE; KAPLAN MEIER METHOD; LONGITUDINAL STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS;

AGED; ANTILIPEMIC AGENTS; BEZAFIBRATE; COLONIC NEOPLASMS; CORONARY ARTERY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; KAPLAN-MEIERS ESTIMATE; LIGANDS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 46649088002     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-7-18     Document Type: Article

References (38)

1. Mutoh M Niho N Wakabayashi K: Concomitant suppression of hyperlipidemia and intestinal polyp formation by increasing lipoprotein lipase activity in Apc-deficient mice. Biol Chem 2006, 387:381-385. 10.1515/BC.2006.051 16606335
2. Komninou D Ayonote A Richie JP Jr Rigas B: Genomics, transcriptomics, proteomics, and numbers. Arch Pathol Lab Med 2003, 127:1089-1097. 12946210
3. Giovannucci E: Insulin and colon cancer. Cancer Causes Control 1995, 6:164-179. 10.1007/BF00052777 7749056
4. McKeown-Eyssen G: Epidemiology of colorActal cancer revisited: are serum triglycerides and/or plasma glucose associated with risk?. Cancer Epidemiol Biomarkers Prev 1994, 3:687-695. 7881343
5. Tabuchi M Kitayama J Nagawa H: Hypertriglyceridemia is positively correlated with the development of colorectal tubular adenoma in Japanese men. World J Gastroenterol 2006, 12:1261-1264. 16534881
6. Bruce WR Wolever TM Giacca A: Mechanisms linking diet and colorectal cancer: The possible role of insulin resistance. Nutr Cancer 2000, 37:19-26. 10.1207/S15327914NC3701_2 10965515
7. Yamada K Araki S Tamura M Sakai I Takahashi Y Kashihara H Kono S: Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998, 27:794-798. 10.1093/ije/27.5.794 9839735
8. Slattery ML Curtin K Wolff R Ma KN Sweeney C Murtaugh M Potter JD Levin TR Samowitz W: PPARgamma and coloA and rectal cancer: associations with specific tumor mutations, aspirin, ibuprofen and insulin-related genes (United States). Cancer Causes Control 2006, 17:239-249. 10.1007/ s10552-005-0411-6 16489531
9. Tanaka T Kohno H Yoshitani S Takashima S Okumura A Murakami A Hosokawa M: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001, 61:2424-2428. 11289109
10. Matthiessen MW Pedersen G Albrektsen T Adamsen S Fleckner J Brynskov J: Peroxisome proliferator-activated receptor expression and activation in normal human colonic epithelial cells and tubular adenomas. Scand J Gastroenterol 2005, 40:198-205. 10.1080/00365520410009573 15764152
11. RosenAED Spiegelman BM: PPARgamma: a nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001, 276:37731-37734. 10.1074/jbc.M106424200 11459852
12. Niho N Takahashi M Kitamura T Shoji Y Itoh M Noda T Sugimura T Wakabayashi K: Concomitant suppression of hyperlipidemia and intestinal polyp formation in Apc-deficient mice by peroxisome proliferator-activated receptor ligands. Cancer Res 2003, 63:6090-6095. 14522940
13. Kohno H Suzuki R Sugie S Tanaka T: Suppression of colitis-related mouse colon carcinogenesis by a COX-2 inhibitor and PPAR ligands. BMC Cancer 2005, 5:46. 1156872 15892897 10.1186/1471-2407-5-46
14. Tanaka T Kohno H Yoshitani S Takashima S Okumura A Murakami A Hosokawa M: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res 2001, 61:2424-2428. 11289109
15. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study. Circulation 2000, 102:21-27. 10880410
16. Barchana M Liphshitz I Rozen P: Trends in colorectal cancer incidence and mortality in the Israeli Jewish ethnic populations. Fam Cancer 2004, 3:207-214. 10.1007/s10689-004-9546-y 15516843
17. Israel Cancer Registry - 1997 Jerusalem, Israel: Ministry of Health 2001 http://www.health.gov.il/pages/default.asp?maincat=22 February 25, 2008
18. Fishler Y Chitrit A Barchana M Modan B: Examination of Israel national cancer data accumulation completeness for 1991 The National Center for Disease Control, Publication No. 230, Tel Hashomer, Israel 2003
19. Colangelo LA Gapstur SM Gann PH Dyer AR Liu KL: Colorectal cancer mortality and factors related to the insulin resistance syndrome. Cancer Epidemiol Biomarkers Prev 2002, 11:385-391. 11927499
20. Trevisan M Liu J Muti P Misciagna G Menotti A Fucci F: Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001, 10:937-941. 11535544
21. Schoen RE Tangen CM Kuller LH Burke GL Cushman M Tracy RP Dobs A Savage PJ: Increased blood glucose and insulin, body size, and incident colorectal cancer. J Natl Cancer Inst 1999, 91:1147-1154. 10.1093/jnci/ 91.13.1147 10393723
22. Morita T Tabata S Mineshita M Mizoue T Moore MA Kono S: The metabolic syndrome is associated with increased risk of colorectal adenoma development: The Self-Defense Forces health study. Asian Pac J Cancer Prev 2005, 6:485-489. 16435997
23. Cowey S Hardy RW: The metabolic syndrome: A high-risk state for cancer?. Am J Pathol 2006, 169:1505-1522. 1780220 17071576 10.2353/ ajpath.2006.051090
24. Nilsen TI Vatten LJ: Prospective study of colorectal cancer risk and physical activity, diabetes, blood glucose and BMI: Exploring the hyperinsulinaemia hypothesis. Br J Cancer 2001, 84:417-422. 10.1054/ bjoc.2000.1582 11161410
25. Giovannucci E: Insulin, insulin-like growth factoAs and colon cancer: a review of the evidence. J Nutr 2001, 131:3109S-3120S. 11694656
26. Peroxisome proliferator-activated receptor gamma: A novel target for cancer therapeutics? Anticancer Drugs 2007, 18:237-244. 10.1097/ CAD.0b013e328011e67d 17264754
27. Thompson EA: PPARgamma physiology and pathology in gastrointestinal epithelial cells. Mol Cells 2007, 24:167-176. 17978568
28. Hollingshead HE Borland MG Billin AN Willson TM Gonzalez FJ Peters JM: Ligand activation of peroxisome proliferator-activated receptor-{beta}/ {delta} (PPAR{beta}/{delta}) and inhibition of cyclooygenase-2 (COX2) attenuate colon carcinogenesis through independent signaling mechanisms. Carcinogenesis 2008, 29:169-176. 10.1093/carcin/bgm209 17893232
29. Tenenbaum A Fisman EZ Motro M: Metabolic syndrome and type 2 diabetes mellitus: Focus on peroxisome proliferator activated receptors (PPAR). Cardiovasc Diabetol 2003, 2:4. 153546 12834541 10.1186/1475-2840-2-4
30. Libby P Plutzky J: InflammatiRn in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists. Am J Cardiol 2007, 99(4A):27B-40B. 10.1016/j.amjcard.2006.11.004 17307056
31. Tenenbaum A Motro M Fisman EZ: Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: The bezafibrate lessons. Cardiovasc Diabetol 2005, 4:14. 1236941 16168052 10.1186/ 1475-2840-4-14
32. WillsFn TM Brown PJ Sternbach DD Henke BR: The PPARs: from orphan receptors to drug discovery. J Med Chem 2000, 43:527-550. 10.1021/ jm990554g 10691680
33. Peters JM Aoyama T Burns AM Gonzalez FJ: Bezafibrate is a dual ligand for PPARalpha and PPARbeta: Studies using null mice. Biochim Biophys Acta 2003, 1632:80-89. 12782154
34. Poirier H Rouault C Clément L Niot I Monnot MC Guerre-Millo M Besnard P: Differential involvement of peroxisome-proliferator-activated receptors alpha and delta in fibrate and fatty-acid-mediated inductions of the gene encoding liver fatty-acid-binding protein in the liver and the small intestine. Biochem J 2001, 355:481-488. 1221761 11284737 10.1042/0264-6021:3550481
35. Vázquez M Roglans N Cabrero A Rodríguez C Adzet T Alegret M Sánchez RM Laguna JC: Bezafibrate induces acyl-CoA oxidase mRNA levels and fatty acid peroxisomal beta-oxidation in rat white adipose tissue. Mol Cell Biochem 2001, 216:71-78. 10.1023/A:1011060615234 11216866
36. Nagasawa T Inada Y Nakano S Tamura T Takahashi T Maruyama K Yamazaki Y Kuroda J Shibata N: Effects of bezafibrate, PPAR pan-agonist, and GW50 PPARdelta agonist, on development of steatohepatitis in mice fed a methionine- and choline-deficient diet. Eur J Pharmacol 1516, 536(1-2):182-91. 10.1016/j.ejphar.2006.02.028 16574099
37. Tenenbaum A Motro M Fisman EZ Schwammenthal E Adler Y Goldenberg I Leor J Boyko V Mandelzweig L Behar S: Peroxisome proliferator-activated receptors ligand bezafibrate for prevention of type 2 diabetes mellitus in patients with coronary artery disease. Circulation 2004, 109:2197-2202. 10.1161/01.CIR.0000126824.12785.B6 15123532
38. Despres JP Lemieux I Robins SJ: Role of fibric acid derivatives in the management of risk factors for coronary heart disease. Drugs 2004, 64:2177-2198. 10.2165/00003495-200464190-00003 15456334